Takatani, A., Koga, T., Fujita, Y., Fukui, S., Endo, Y., Shimizu, T., & Kawakami, A. (2020). Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clinical immunology (Orlando, Fla.), 215, 108451. https://doi.org/10.1016/j.clim.2020.108451
Style de citation ChicagoTakatani, Ayuko, Tomohiro Koga, Yuya Fujita, Shoichi Fukui, Yushiro Endo, Toshimasa Shimizu, et Atsushi Kawakami. "Efficacy of Tofacitinib for Slowly Progressive Interstitial Lung Disease in a Patient with Anti-MDA5 Antibody-positive Dermatomyositis." Clinical Immunology (Orlando, Fla.) 215 (2020): 108451. https://dx.doi.org/10.1016/j.clim.2020.108451.
Style de citation MLATakatani, Ayuko, et al. "Efficacy of Tofacitinib for Slowly Progressive Interstitial Lung Disease in a Patient with Anti-MDA5 Antibody-positive Dermatomyositis." Clinical Immunology (Orlando, Fla.), vol. 215, 2020, p. 108451.